Weight management and type 2 diabetes
Cagrilintide + semaglutide (CagriSema)
REDEFINE 1 showed -20.4% mean weight change versus -3.0% placebo at 68 weeks in obesity; 2026 REIMAGINE 2 found the 2.4/2.4 mg combination statistically.
Exact-combination evidence
Multiple randomized Phase II/III combination trials
REDEFINE 1 showed -20.4% mean weight change versus -3.0% placebo at 68 weeks in obesity; 2026 REIMAGINE 2 found the 2.4/2.4 mg combination statistically superior to semaglutide 2.4 mg for HbA1c in T2D. Integrity note: Combination evidence must stay separate from cagrilintide monotherapy; REIMAGINE 2 has a published erratum that must be linked.
Human combination evidence
Yes — REDEFINE 1/2 and REIMAGINE programmes
Combination safety
Yes — trial safety datasets